Todd Harris has been appointed CEO of Tyra Biosciences.
4 reports, 2 independent
Updated Aug 22
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Todd Harris has been appointed CEO of Tyra Biosciences.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Tyra Biosciences
company in Carlsbad, United States
Nothing else this week.
-
Todd Harris
researcher
Nothing else this week.
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaTyra Biosciences initiates paediatric study for achondroplasia treatment US-based Tyra Biosciences has dosed the first paediatric participant in the dose-escalation/dose-expansion Phase II BEACH301 t
- PR NewswireTyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia -Dabogratinib is the only oral FGFR3-selective inhibitor in clinica
- PR NewswireTyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights - Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equiv
- PR NewswireTyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series CARLSBAD, Calif., July 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasd